Thai FDA Supports the Advanced Medical Industry by Hosting FDA EXPO 2026, Driving Thailand’s ATMPs onto the Global Stage; MEDEZE Showcases Its Comprehensive ATMP Sandbox Capabilities
The Thai Food and Drug Administration (Thai FDA) continues to actively support the development of Advanced Therapy Medicinal Products (ATMPs) through a national-level EXPO platform. MEDEZE was selected as one of the key showcases, reflecting Thailand’s readiness in precision medicine and biomedical innovation.
Thailand is entering a new era of advanced medical development, particularly in the field of Advanced Therapy Medicinal Products (ATMPs), which represent one of the country’s high-potential target industries—both in terms of public healthcare enhancement and future economic value creation. The Thai FDA has taken a proactive role in strengthening the ATMP ecosystem through the organization of FDA EXPO 2026, held under the theme “From Local to Global: Pathway to Global Wellness.” The event aims to elevate Thai health products to international standards and provides a central platform for businesses, innovators, and consumers to connect knowledge, technology, and market opportunities in one place.
FDA EXPO 2026 also serves as a national hub linking innovation, regulatory standards, and medical safety, while advancing the establishment of a structured ATMP Sandbox to support critical clinical trials within Thailand.
On this occasion, Mr. Anutin Charnvirakul, Prime Minister and Minister of the Interior, presided over the opening ceremony and addressed Thailand’s direction in advancing the advanced medical industry. He emphasized that food and medicines are fundamental pillars of human security and national security. Lessons learned from recent global crises—including emerging infectious diseases, climate change, and geopolitical conflicts—have demonstrated that countries capable of achieving self-reliance in food and pharmaceuticals are better equipped to manage crises and achieve sustainable development.
Thailand possesses strong food security, a robust agricultural sector, abundant natural resources, rich biodiversity, and valuable local wisdom—all of which form a critical foundation for long-term national resilience. The country should therefore move beyond being merely an exporter of food and pharmaceutical products toward becoming a global partner and hub for food security, by upgrading value-added processing, innovation development, and brand building that reflect quality and safety throughout the entire supply chain.
At the same time, Thai herbal products and health-related innovations represent key national strengths that help enhance pharmaceutical security and reduce reliance on imports. In this regard, the Thai FDA continues to play a vital role in regulating standards, ensuring safety, and building confidence among both domestic and international consumers.
Dr. Veerapol Khemarangsan, Chief Executive Officer of Medeze Group Public Company Limited, or MEDEZE, stated that government policies supporting the development of Advanced Therapy Medicinal Products (ATMPs) serve as a critical mechanism in driving Thailand’s advanced medical industry forward. These policies help elevate research and innovation to international standards while creating opportunities for public–private collaboration in developing high-potential medical products, enabling Thai patients to gain greater access to safe and effective treatments.
MEDEZE was presented as one of the key advanced medical showcases at the event, reflecting the readiness of Thailand’s private sector to actively support and implement national ATMP policies in a tangible manner.
As one of the leaders in stem cell banking and cell cultivation, with extensive experience and internationally accredited standards, MEDEZE is well positioned to advance research and development in ATMPs under the government’s policy framework and support mechanisms. Currently, MEDEZE is the only private company in Thailand to receive approval for an ATMP Sandbox project, a pilot clinical research initiative covering four disease groups: osteoarthritis and anti-aging medicine in collaboration with Bang Rak Medical Center under the Department of Disease Control; as well as degenerative disc disease and skin regeneration in collaboration with Vachira Phuket Hospital.
MEDEZE has entered into memoranda of understanding with government agencies to establish pilot medical facilities, providing comprehensive support including laboratory infrastructure, manufacturing facilities, products, and research funding.
The Thai FDA’s initiative to provide both an EXPO platform and an ATMP Sandbox is a key mechanism in bridging the gap between research and real-world application, serving as a powerful driver for Thailand’s sustainable advancement in medical innovation. This approach reflects the nation’s policy direction, which places equal emphasis on innovation, regulatory standards, and safety. In this context, MEDEZE stands as a clear example of a Thai private-sector organization ready to support the practical and sustainable implementation of the ATMP ecosystem.
For more information, please visit: https://www.medezegroup.com/th/
IR Press Releases
